
News|Articles|October 9, 2025
ESMO 2025 Will See Novel Agents Emerge and Standard Strategies Shift in GI Oncology
Author(s)Ashling Wahner
Fact checked by: Caroline Seymour
Ahead of the 2025 ESMO Congress, GI cancer experts share the gastric cancer and CRC research they’re most looking forward to seeing at the meeting.
Advertisement
Advertisement
From further clarifying the role of PD-(L)1 inhibition in gastric cancer and colorectal cancer (CRC), to demonstrating the potential predictive value of minimal residual disease (MRD) negativity in late-stage colon cancer, gastrointestinal oncology data presented at the
Related to this article

Daraxonrasib plus gemcitabine/nab-paclitaxel yielded a 60.7% ORR and 12.8-month median PFS in first-line metastatic pancreatic adenocarcinoma.

The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.

Sac-TMT improved OS vs treatment of physician’s choice in pretreated gastroesophageal adenocarcinoma, but TroFuse-015 missed its PFS secondary end point.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA granted priority review to sonesitatug vedotin for previously treated CLDN18.2-positive advanced gastroesophageal cancers.

Narek Shaverdian, MD, outlines how novel strategies may reshape unresectable stage III NSCLC management.
Advertisement
Advertisement


